Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend and Broaden their Research and Development Agreement

January, 2022

Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended and broadened its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of research and early development of NOMAD’s R&D pipeline product candidates, including but not limited to, antibacterial proteins for control of multi-drug and pan-drug resistant pathogenic Gram-negative bacteria (Klebsiella, Escherichia, Pseudomonas, Salmonella) as well as antiviral proteins lectins for prevention and early therapy of enveloped viruses including coronaviruses, influenza viruses and immunodeficiency viruses. Agreement provides NOMAD with broader access to FRAUNHOFER expertise and research capabilities in areas of new drug development such as immunology, assay development and validation, pharmacokinetics and pharmacodynamics studies, toxicology, in vitro and in vivo testing, including animal model development, validation and efficacy studies, some of those in FRAUNHOFER’s S3 biocontainment facility.

The financial aspects of Agreement are not disclosed.

„We are very pleased to broaden the existing Agreement“, said Prof. Yuri Gleba, NOMAD’s CEO. “NOMAD is one of only few companies developing antibacterial and antiviral biologics of entirely new classes, and we intend to quickly and aggressively develop our products and bring them to the market through partnerships with strategic partners. One such partner essential to our preclinical development efforts is FRAUNHOFER. Our past collaboration has been highly successful, and it allowed us to significantly accelerate our research and development programs. I view our collaboration as an exemplary relationship.”

About Nomad Bioscience GmbH
Nomad Bioscience, headquartered in Munich, Germany, is a private biotechnology company developing antibacterial and antiviral biopharmaceuticals that address critical unmet needs. Nomad’s product pipeline consists of several selected protein candidates for human health including precision biologics bacteriocins, including colicins, lysins and other bacteriocins, antiviral proteins such as griffithsin and other lectins. Nomad’s plant-based transient protein expression technologies are licensed to several companies for a broad range of products. The Company is actively seeking corporate partners to help develop and commercialize its products.
Contact info: gleba@nomadbioscience.com

About Fraunhofer Institute for Cell Therapy and Immunology
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and
One of the institute’s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products within the business fields cell and gene therapy, drugs and vaccines, molecular diagnostics and immunodiagnostics, as well as extracorporeal therapies. Its areas of competence lie in cell biology, immunology, drug biochemistry, bioanalytics and bioproduction as well as process development and automation. Research in these areas is centered around developments in immuno-oncology and infectious disease pathology. The S3 safety laboratory allows research and development activities to be conducted and highly pathogenic agents investigated under biosafety level 3 conditions.

The institute works in close cooperation with hospital institutions and performs quality tests besides manufacturing investigational medicinal products in line with GMP requirements. Furthermore, it supports partners in developing processes for the pharmaceutical production of ATMPs and biologicals, for example by helping them to obtain manufacturing licenses.